HALO
Halozyme Therapeutics Inc.
$42.4
Earnings Summary
Revenue | $117.28Mn |
Net Profits | $60.11Mn |
Net Profit Margins | 51.25% |
PE Ratio | 17.17 |
Highlights
Halozyme Therapeutics Inc.’s revenue jumped 31.74% since last year same period to $117.28Mn in the Q1 2022. On a quarterly growth basis, Halozyme Therapeutics Inc. has generated 14.98% jump in its revenue since last 3-months.
Halozyme Therapeutics Inc.’s net profit jumped 115.48% since last year same period to $60.11Mn in the Q1 2022. On a quarterly growth basis, Halozyme Therapeutics Inc. has generated -9.98% fall in its net profits since last 3-months.
Halozyme Therapeutics Inc.’s net profit margin jumped 63.56% since last year same period to 51.25% in the Q1 2022. On a quarterly growth basis, Halozyme Therapeutics Inc. has generated -21.7% fall in its net profit margins since last 3-months.
Halozyme Therapeutics Inc.’s price-to-earnings ratio after this Q1 2022 earnings stands at 17.17.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Halozyme Therapeutics Inc. post its latest quarter earnings
EPS Estimate Current Quarter | 0.5 |
EPS Estimate Current Year | 0.5 |
Highlights
Halozyme Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.5 - a 2.04% jump from last quarter’s estimates.
Halozyme Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at 0.5.
Key Ratios
Key ratios of the Halozyme Therapeutics Inc. post its Q1 2022 earnings
Earning Per Share (EPS) | 0.47 |
Return on Assets (ROA) | 0.11 |
Return on Equity (ROE) | 1.77 |
Dividend Per Share (DPS) | 0 |
Highlights
Halozyme Therapeutics Inc.’s earning per share (EPS) jumped 27.03% since last year same period to 0.47 in the Q1 2022. This indicates that the Halozyme Therapeutics Inc. has generated 27.03% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics Inc.’s return on assets (ROA) stands at 0.11.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics Inc.’s return on equity (ROE) stands at 1.77.
Halozyme Therapeutics Inc. declared 0 dividend per share during the earnings announcement for Q1 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-10 | 0.49 | 0.47 | -4.08% |
Company Information
Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.
Organisation | Halozyme Therapeutics Inc. |
Headquarters | San Diego, California, US |
Employees | 136 |
Industry | Health Technology |
CEO | Helen Torley |